Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personal care accountability

This article was originally published in The Tan Sheet

Executive Summary

Consumers of personal care products are increasingly growing more savvy and health-conscious, holding personal-care firms accountable for product ingredients and the health of communities in which they manufacture, according to Terry Burstein, interim chair of fashion at the Laboratory Institute of Merchandising in New York. Mirroring trends in the food market, consumers have become more interested in the natural/organic realm due largely to the work of consumer advocacy groups such as the Campaign for Safe Cosmetics. Natural marketers will likely be expected to back up formula claims and play a more visible role in educating consumers on what "natural" and "organic" mean, the executive notes. In July, a Natural Products Association work group announced plans to develop a standard definition for the term "natural" in personal care (1"The Tan Sheet" Aug. 20, 2007, p. 10)...

You may also be interested in...



Natural Dentist’s Rinse Highlights Challenges Of Defining “Natural”

This fall, The Natural Dentist's Healthy Gums Daily Oral Rinse will feature a new naturally derived ingredient to replace the sole artificial ingredient in its current formulation, according to CEO Nancy Rosenzweig

Long Hot Summer Forecast At US FDA For Novel Drug Reviews

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS101162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel